Literature DB >> 448155

Studies on in vivo priming of the TNP-reactive cytotoxic effector cell system. I. Comparison of the effects of intravenous inoculation with TNP-conjugated cells on the development of contact sensitivity and cell-mediated lympholysis.

H Fujiwara, R B Levy, G M Shearer, W D Terry.   

Abstract

A comparison was made of the effects of i.v. inoculation of trinitrophenyl-(TNP) conjugated syngeneic cells on the subsequent in vitro generation of TNP-reactive effector cell activity and on the in vivo development of TNP-contact sensitivity. The administration of syngeneic TNP-conjugated spleen cells before 2,4,6-trinitro-1-chlorobenzene (TNCB) painting abolished the capability of animals to develop TNP-contact sensitivity. In contrast, the same treatment resulted in an appreciable augmentation in the generation of TNP-reactive cytotoxic effector cell activity as measured by subsequent in vitro sensitization with TNP-conjugated cells. The possible mechanisms by which enhanced TNP-reactive cytotoxic effector cell activity was elicited under conditions identical to those that induced unresponsiveness for TNP-contact sensitivity are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 448155

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.

Authors:  P M Comoglio; M Prat; S Bretti
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

2.  T-cell suppression and contrasuppression induced by histamine H2 and H1 receptor agonists, respectively.

Authors:  J N Siegel; A Schwartz; P W Askenase; R K Gershon
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

3.  Two distinct mechanisms regulate the in vivo generation of cytotoxic T cells.

Authors:  M S Sy; S H Lee; M Tsurufuji; K L Rock; B Benacerraf; R Finberg
Journal:  J Exp Med       Date:  1982-09-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.